Comparison between GATA2 and DDX41-mutated myeloid neoplasms
Authors:
- 23 August 2022
- journal article
- editorial
- Published by Elsevier in Leukemia Research
- Vol. 121, 106931
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk diseaseAmerican Journal of Hematology, 2019
- Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and ControversiesCurrent Hematologic Malignancy Reports, 2018
- Myeloid neoplasms with germline DDX41 mutationInternational Journal of Hematology, 2017
- DDX41-related myeloid neoplasiaSeminars in Hematology, 2017
- GATA2 deficiency and related myeloid neoplasmsSeminars in Hematology, 2017
- Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignanciesBlood, 2016
- Inherited and Somatic Defects in DDX41 in Myeloid NeoplasmsCancer Cell, 2015
- GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemiaBlood, 2012
- GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosisLeukemia, 2012
- Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemiaProceedings of the National Academy of Sciences, 2008